Response Genetics Expands Distribution of ResponseDX Testing into Mexico
By LabMedica International staff writers Posted on 20 May 2014 |
Response Genetics, Inc. (Los Angeles, CA, USA) has completed a commercial agreement with DxM Diagnostico Molecular (DIFRA), a leading distributor for cancer testing in Mexico, to offer the ResponseDX testing services to patients throughout Mexico.
The agreement covers the ResponseDX Tissue of Origin test and other targeted molecular tests in the Response Genetics portfolio. The Tissue of Origin test is a US Food and Drug Administration (FDA; Silver Spring, MD, USA)-cleared test that uses gene expression analysis to provide a definitive diagnosis for poorly-differentiated or metastatic cancers without a clear primary origin. The test was acquired by Response Genetics in August 2013 and reintroduced to the market in February 2014.
Thomas Bologna, chairman and CEO of Response Genetics, said, "We believe the ResponseDX offerings, including our proprietary Tissue of Origin test provides differentiated content to effectively pursue international market opportunities. One of our initiatives is to increase access to our testing services both domestically and internationally. DIFRA will facilitate access to the full complement of our portfolio to Mexican oncologists and pathologists.
Response Genetics, Inc. Clinical Laboratory Improvement Amendments (CLIA)-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists.
Related Links:
Response Genetics, Inc.
US Food and Drug Administration
The agreement covers the ResponseDX Tissue of Origin test and other targeted molecular tests in the Response Genetics portfolio. The Tissue of Origin test is a US Food and Drug Administration (FDA; Silver Spring, MD, USA)-cleared test that uses gene expression analysis to provide a definitive diagnosis for poorly-differentiated or metastatic cancers without a clear primary origin. The test was acquired by Response Genetics in August 2013 and reintroduced to the market in February 2014.
Thomas Bologna, chairman and CEO of Response Genetics, said, "We believe the ResponseDX offerings, including our proprietary Tissue of Origin test provides differentiated content to effectively pursue international market opportunities. One of our initiatives is to increase access to our testing services both domestically and internationally. DIFRA will facilitate access to the full complement of our portfolio to Mexican oncologists and pathologists.
Response Genetics, Inc. Clinical Laboratory Improvement Amendments (CLIA)-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists.
Related Links:
Response Genetics, Inc.
US Food and Drug Administration
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance